Abstract
We assessed the anti-V3 antibody content and viral neutralization potential of the plasma of 63 HIV-1-infected patients (antiretroviral naïve=39, treated=24) against four primary isolates (PIs) of clade C and a tier 1 clade B isolate SF162. Depletion and inhibition of anti-V3 antibodies in the plasma of five patients with high titers of anti-V3 antibodies led to modest change in the neutralization percentage against two PIs (range 0–21%). The plasma of antiretroviral-treated patients exhibited higher neutralization potential than that of the drug-naïve plasmas against the four PIs tested which was further evidenced by a follow-up study.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dreyer, K., Kallas, E.G., Planelles, V., Montefiori, D., McDermott, M.P., Hasan, M.S., and Evans, T.G. 1999. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses 15, 1563–1571.
Fouts, T.R., Binley, J.M., Trkola, A., Robinson, J.E., and Moore, J.P. 1997. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71, 2779–2785.
Frost, S.D., Wrin, T., Smith, D.M., Kosakovsky Pond, S.L., Liu, Y., Paxinos, E., Chappey, C., Galovich, J., Beauchaine, J., Petropoulos, C.J., and et al. 2005. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 102, 18514–18519.
Huang, C.C., Tang, M., Zhang, M.Y., Majeed, S., Montabana, E., Stanfield, R.L., Dimitrov, D.S., Korber, B., Sodroski, J., Wilson, I.A., and et al. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310, 1025–1028.
Kim, J.H., Mascola, J.R., Ratto-Kim, S., VanCott, T.C., Loomis-Price, L., Cox, J.H., Michael, N.L., Jagodzinski, L., Hawkes, C., Mayers, D., and et al. 2001. Selective increases in HIV-specific neutralizing antibody and partial reconstitution of cellular immune responses during prolonged, successful drug therapy of HIV infection. AIDS Res. Hum. Retroviruses 17, 1021–1034.
Kulkarni, S., Tripathy, S., Gangakhedkar, R., Jadhav, S., Agnihotri, K., Sane, S., Bollinger, R., and Paranjape, R. 2008. Neutralizing antibody responses in recent seroconverters with HIV-1 subtype C infections in India. AIDS Res. Hum. Retroviruses 24, 1159–1166.
Lakhashe, S.K., Kulkarni, S.S., Thakar, M.R., Ghate, M.V., and Paranjape, R.S. 2007. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV-1. Virology 359, 295–301.
Li, M., Gao, F., Mascola, J.R., Stamatatos, L., Polonis, V.R., Koutsoukos, M., Voss, G., Goepfert, P., Gilbert, P., Greene, K.M., and et al. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125.
Morris, L., Binley, J.M., Clas, B.A., Bonhoeffer, S., Astill, T.P., Kost, R., Hurley, A., Cao, Y., Markowitz, M., Ho, D.D., and et al. 1998. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 188, 233–245.
Nandi, A., Lavine, C.L., Wang, P., Lipchina, I., Goepfert, P.A., Shaw, G.M., Tomaras, G.D., Montefiori, D.C., Haynes, B.F., Easterbrook, P., and et al. 2010. Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. Virology 396, 339–348.
Ozkaya Sahin, G., Bowles, E.J., Parker, J., Uchtenhagen, H., Sheik-Khalil, E., Taylor, S., Pybus, O.G., Makitalo, B., Walther-Jallow, L., Spangberg, M., and et al. 2010. Generation of neutralizing antibodies and divergence of SIVmac239 in cynomolgus macaques following short-term early antiretroviral therapy. PLoS Pathog. 6, e1001084.
Parren, P.W., Burton, D.R., and Sattentau, Q.J. 1997. HIV-1 antibody-debris or virion? Nat. Med. 3, 366–367.
Richman, D.D., Wrin, T., Little, S.J., and Petropoulos, C.J. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100, 4144–4149.
Sarmati, L., Nicastri, E., el-Sawaf, G., Ventura, L., Salanitro, A., Ercoli, L., Vella, S., and Andreoni, M. 1997. Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (Invirase) treatment. J. Med. Virol. 53, 313–318.
Schuitemaker, H. and Kootstra, N.A. 2005. Isolation, propagation, and titration of human immunodeficiency virus type 1 from peripheral blood of infected individuals. Methods Mol. Biol. 304, 17–24.
Spenlehauer, C., Saragosti, S., Fleury, H.J., Kirn, A., Aubertin, A.M., and Moog, C. 1998. Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1. J. Virol. 72, 9855–9864.
Stanfield, R.L., Gorny, M.K., Zolla-Pazner, S., and Wilson, I.A. 2006. Crystal structures of human immunodeficiency virus type 1 (HIV-1) neutralizing antibody 2219 in complex with three different V3 peptides reveal a new binding mode for HIV-1 cross-reactivity. J. Virol. 80, 6093–6105.
Wei, X., Decker, J.M., Wang, S., Hui, H., Kappes, J.C., Wu, X., Salazar-Gonzalez, J.F., Salazar, M.G., Kilby, J.M., Saag, M.S., and et al. 2003. Antibody neutralization and escape by HIV-1. Nature 422, 307–312.
Zolla-Pazner, S., Cohen, S.S., Krachmarov, C., Wang, S., Pinter, A., and Lu, S. 2008. Focusing the immune response on the V3 loop, a neutralizing epitope of the HIV-1 gp120 envelope. Virology 372, 233–246.
Author information
Authors and Affiliations
Corresponding author
Additional information
These authors contributed equally to this work.
Rights and permissions
About this article
Cite this article
Choudhary, A.K., Andrabi, R., Prakash, S.S. et al. Neutralization potential of the plasma of HIV-1 infected Indian patients in the context of anti-V3 antibody content and antiretroviral theraphy. J Microbiol. 50, 149–154 (2012). https://doi.org/10.1007/s12275-012-1246-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12275-012-1246-y